SAN DIEGO, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), an oncology diagnostics company focused on improving individual patient treatment, announced today the closing of its previously announced initial public offering of 1,900,000 shares of common stock, at a public offering price of $10.00 per share. The gross proceeds to Biocept from the offering were $19,000,000, before deducting underwriting discounts and commissions and other offering expenses payable by Biocept.
Aegis Capital Corp. and Feltl and Company, Inc. acted as joint book-running managers for the offering.
MLV & Co. LLC acted as a co-manager for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 4, 2014. In addition, a supplemental registration statement relating to these securities was filed with the Securities and Exchange Commission on February 4, 2014 and automatically became effective.
This offering was made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: email@example.com. Investors may also obtain these documents at no cost by visiting the SEC's website at http://www.sec.gov.
Biocept has granted the representative of the underwriters a 45-day option to purchase up to 285,000 additional shares of common stock to cover over-allotments, if any.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Biocept, Inc., headquartered in San Diego, California, is a commercial stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its technology platforms to help improve individual patient treatment. Biocept has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BRTM test for breast cancer and plans to introduce tests for other solid tumors.
CONTACT: Investor Contact: The Ruth Group Lee Roth/David Burke (646) 536-7012 / (646) 536-7009 firstname.lastname@example.org / email@example.com Media Contact: The Ruth Group Melanie Sollid-Penton (646) 536-7023 firstname.lastname@example.orgSource:Biocept, Inc.